HOLON, Israel, March 26, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025: H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development ConferenceDate: Wednesday, April 2, 2025Format: Fireside chat and 1x1 meetingsFireside chat time: 9:30 am ET 24th Annual Needham Virtual Healthcare ConferenceDate: Monday, April 7, 2025Format: Fireside chat and 1x1 meetingsFireside chat time: 8:00 am ET Stifel's 2025 Virtual Targeted Oncology ForumDate: Wednesday, April 9, 2025Form

In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combina

Oppenheimer initiated coverage of Compugen with a rating of Outperform and set a new price target of $4.00

Jefferies downgraded Compugen from Buy to Hold and set a new price target of $2.00

Oppenheimer reiterated coverage of Compugen with a rating of Outperform and set a new price target of $14.00 from $17.00 previously

20-F - COMPUGEN LTD (0001119774) (Filer)

6-K - COMPUGEN LTD (0001119774) (Filer)

SCHEDULE 13G/A - COMPUGEN LTD (0001119774) (Subject)

Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio

HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Coh

In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combina

HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.  Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following lin

SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

SC 13G/A - COMPUGEN LTD (0001119774) (Subject)